James Campbell, M.D., seeks new opportunities to invest in innovative technologies in the areas of therapeutics and devices, and he works with entrepreneurs at the early stages of company formation. Dr. Campbell sits on the boards of Anesiva (NASDAQ: ANSV, an IW portfolio company), Detroit Trading Company, Arcion Therapeutics, and Amplimmune (an IW portfolio company). He is also the Founder and Chairman of the Board of the non-profit organization, the American Pain Foundation.
Campbell has a long record of accomplishment in academic medicine and neuroscience research. He serves as Professor of Neurosurgery and Director of the Blaustein Pain Treatment Center in the Johns Hopkins University School of Medicine, and in the past served as Director of the Residency Training Program for the Department of Neurosurgery at Johns Hopkins. He has served as the chief editor of several books, published well over 100 peer-reviewed research papers, and serves on the editorial board of several academic journals. Campbell has received many national awards for research and public service including the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health, and the Grass Award from the Society of Neurological Surgery. He also has received the Kerr Award for Research from the American Pain Society. He has served as consultant/advisory boards for several biopharmaceutical companies and holds many patents in the life sciences.
Campbell received his bachelor’s degree from the University of Michigan with high honors and high distinction, and his M.D. from Yale University. He completed his residency in Neurosurgery at The Johns Hopkins University, and also pursued post-doctoral training in neurophysiology in the Department of Physiology at Johns Hopkins. Campbell is a diplomat of the American Board of Neurological Surgery.